Drug intelligence / Profile preview

REGN1154

Development stage: Phase 1
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

REGN1154 is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals. It was investigated in a first-in-human Phase 1 clinical trial to assess its safety and tolerability when administered intravenously or subcutaneously in healthy volunteers. The specific molecular target and mechanism of action for REGN1154 have not been publicly disclosed. There are references suggesting it may be related to allergy treatment, but no definitive mechanistic or indication data are available from published sources[1][2][3][7][10].

Targets

IL33 (IL-33)

Beyond the preview

Go deeper on REGN1154.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGN1154.

Explore the full profile